Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Cardiorentis

    Novartis day

    Novartis’ Extavia evades NICE restrictions on MS drugs

    But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

    - PMLiVE

    Merck Serono signs agreement to develop antimalarial therapy

    Deal means the German firm obtains rights to candidate DDD107498

    - PMLiVE

    Merck Serono joins CAR-T race with $941m Intrexon deal

    Will collaborate on therapy to recognise and attack antigens on tumour cells

    - PMLiVE

    Galderma removed from list of companies compliant to UK Code

    Follows breach of pharma standards

    - PMLiVE

    Building a business that is lean and specialised

    Tuomo Pätsi on Celgene’s approach to access, marketing and the importance of culture

    - PMLiVE

    Merck Serono brings electronic MS device to six more countries

    RebiSmart works alongside the company's MSdialog web-based software

    Merck KGaA shakes up pharma leadership

    Stefan Oschmann becomes deputy CEO as Belén Garijo assumes more responsibility

    - PMLiVE

    Where is the future for pharma marketing?

    Publicis’ Sam Welch on global shifts in the industry

    - PMLiVE

    Merck Serono pulls development of lung cancer prospect

    Ditches tecemotide immunotherapy to focus on anti-PD1

    - PMLiVE

    Diagnostics are rising up the pharma value chain

    Pharma interview: Anssi Pulkkinen from Roche Diagnostics, Finland on the increasing prominence of diagnostics

    - PMLiVE

    Rebif hit again as competition bites

    Merck Serono’s MS drug continues its struggle for sales in the US and Europe

    - PMLiVE

    Merck Serono enters anti-PD-1 fray

    Moves skin cancer antibody candidate into phase II trials

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links